Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tilrekimig + rHuPH20
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Tilrekimig + rHuPH20 is an investigational combination therapy developed by Pfizer. It consists of tilrekimig (PF-07275315), a trispecific monoclonal antibody, co-formulated with recombinant human hyaluronidase PH20 (rHuPH20). Tilrekimig is designed to simultaneously inhibit three key drivers of Type 2 (Th2) inflammation: interleukin-4 (IL-4), interleukin-13 (IL-13), and thymic stromal lymphopoietin (TSLP). The addition of rHuPH20, an enzyme that temporarily degrades hyaluronan in the subcutaneous space, facilitates the subcutaneous administration of large volumes of the biologic, enhancing absorption and tissue permeability. This combination is being evaluated for chronic inflammatory conditions such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD).
- Other names
- PF-07275315 + rHuPH20
02
Targets
IL-4 (Interleukin 4)IL-13 (Interleukin-13)TSLP (Thymic stromal lymphopoietin)
Beyond the preview
Go deeper on tilrekimig + rHuPH20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tilrekimig + rHuPH20.